PharmaTimes - December 2024

Present tense

So, as we approach the festivities, it’s time for the annual selfrefection jamboree – wallowing in the moments of triumph and castigating perceived failure! Yep, it can only be Christmas, folks.

In order to veer away momentarily from this inevitable personal analysis, I’m here to pull the lens back – way, way back, allowing us to gaze at a much bigger picture.

Indeed, I’m going to pan out so far that I’m framing Planet Earth itself – still home to the most advanced species in the known universe. Us! Unique, hopelessly and unrelentingly alone, but blazing a trail for a brand of progressiveness that only we can know about.

I know what you’re thinking. This is a bit deep, Pinching, where are we going with this?

Well, all roads lead back to one indisputable truth, which across our industry is well worth refecting on.

We remain – perhaps by default – the only form of life that consciously creates and, subsequently, takes chemical-based products that theoretically make life better.

Now, as history has witnessed, this particular road, this decision to intervene with nature, has been far from perfect but our natural curiosity motivates us to persevere. Our curiosity pushes us anew.

And while there is no barometer in terms of humankind’s interaction with pharmaceuticals, it is safe to assume that it has been a force for good.

It is this refection that eases us into another year of decoding the secrets of the pharmaverse.

Merry Christmas!

December 2024 - magazine highlights

Highway to health

Developing futuristic healthcare systems in order to deliv...

How on earth

Decarbonising pharma manufacturing with future state plann...

Outside the box

Comprehending the macrophage swing voter

God bless, Americas!

Clinical Researcher of the Year – The Americas 2024. John...

Altered states

Revised additional risk minimisation guidelines – change f...

Boids zone

How the UK medical cannabis market is tackling supply chai...

On message!

PharmaTimes Marketer of the Year Awards and Communications...

Alive in ’25!

Our luminaries look across the pharmaverse with conclusion...